Treatment Response with Ca-125 in Ovarian Cancer Patients: Comparison among RECIST, WHO, Tridimensional and 3D Volumetric Criteria

被引：0
|
作者：
Oliveira, G. [1 ]
Zondervan, R. [2 ]
Harris, G. [2 ]
Hodge, S. [2 ]
Harisinghani, M. [2 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
AMERICAN JOURNAL OF ROENTGENOLOGY | 2009年 / 192卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Prognostic Role of CA-125 Elimination Rate Constant (KELIM) in Patients with Advanced Epithelial Ovarian Cancer Who Received PARP Inhibitors
    Kim, Ji Hyun
    Kim, Eun Taeg
    Kim, Se Ik
    Park, Eun Young
    Park, Min Young
    Park, Sang-Yoon
    Lim, Myong Cheol
    CANCERS, 2024, 16 (13)
  • [32] D-DIMER AND CA-125 LEVELS IN PATIENTS WITH OVARIAN-CANCER DURING ANTINEOPLASTIC THERAPY - PROGNOSTIC-SIGNIFICANCE FOR THE SUCCESS OF ANTICANCER TREATMENT
    MIRSHAHI, SS
    PUJADELAURAINE, E
    SORIA, C
    MIRSHAHI, M
    FRETAULT, J
    BERNADOU, A
    SORIA, J
    CANCER, 1992, 69 (09) : 2289 - 2292
  • [33] Relationship between pretreatment CA-125 level and risk of relapse in advanced ovarian cancer (AOC) patients in a complete clinical response (CCR) who received "maintenance therapy".
    Liu, PY
    Alberts, DS
    Monk, BJ
    Brady, M
    Markman, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 458S - 458S
  • [34] TUMOR-ASSOCIATED TRYPSIN-INHIBITOR AND CA-125 DURING TREATMENT OF MUCINOUS OVARIAN-CANCER IN 2 PATIENTS
    MOGENSEN, O
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (09) : 1180 - 1181
  • [35] Prognostic role of Ca125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer
    Ferrandina, Gabriella
    Ludovisi, Manuela
    Corrado, Giacomo
    Carone, Vito
    Petrillo, Marco
    Scambia, Giovanni
    GYNECOLOGIC ONCOLOGY, 2008, 109 (02) : 187 - 193
  • [36] SIMULTANEOUS TUMOR-MARKER DETERMINATIONS IN OVARIAN-CANCER PATIENTS - THE NEW CANCER ANTIGEN CA-125 IN COMPARISON TO OTHER TUMOR-MARKERS
    STURM, G
    SCHMIDTRHODE, P
    SCHULZ, KD
    TUMOUR BIOLOGY, 1985, 6 (04): : 420 - 420
  • [37] A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy.
    Liu, P.
    Moon, J.
    Alberts, D. S.
    Monk, B. J.
    Brady, M.
    Markman, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 275S - 275S
  • [38] What are the CA-125 testing rates and their clinical implications among patients with advanced ovarian cancer treated in real-world community practice?
    Duska, Linda
    Cooney, Maureen
    Kiss, Zsofia
    Kalilani, Linda
    Golembesky, Amanda
    Schilder, Jeanne
    Hurteau, Jean
    Randall, Leslie
    Song, Jinlin
    Xiang, Cheryl
    Rabideau, Brendan
    Rimel, Bobbie
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S276 - S277
  • [39] CA-125 SERUM LEVELS CORRELATE WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS - A PROSPECTIVE MULTIINSTITUTIONAL STUDY
    BEREK, J
    KNAPP, R
    MALKASIAN, G
    LAVIN, P
    HACKER, N
    WHITNEY, C
    NILOFF, J
    BAST, R
    GYNECOLOGIC ONCOLOGY, 1986, 23 (02) : 260 - 261
  • [40] Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer
    Bese, Tugan
    Barbaros, Merve
    Baykara, Elif
    Guralp, Onur
    Cengiz, Salih
    Demirkiran, Fuat
    Sanioglu, Cevdet
    Arvas, Macit
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2010, 21 (04) : 248 - 254
12345